U.S. flag

An official website of the United States government

NM_002880.4(RAF1):c.786T>A (p.Asn262Lys) AND Noonan syndrome

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Sep 24, 2014
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:

Allele description [Variation Report for NM_002880.4(RAF1):c.786T>A (p.Asn262Lys)]

NM_002880.4(RAF1):c.786T>A (p.Asn262Lys)

RAF1:Raf-1 proto-oncogene, serine/threonine kinase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Genomic location:
Preferred name:
NM_002880.4(RAF1):c.786T>A (p.Asn262Lys)
  • NC_000003.12:g.12604184A>T
  • NG_007467.1:g.64996T>A
  • NM_001354689.3:c.786T>A
  • NM_001354690.3:c.786T>A
  • NM_001354691.3:c.543T>A
  • NM_001354692.3:c.543T>A
  • NM_001354693.3:c.687T>A
  • NM_001354694.3:c.543T>A
  • NM_001354695.3:c.444T>A
  • NM_002880.4:c.786T>AMANE SELECT
  • NP_001341618.1:p.Asn262Lys
  • NP_001341619.1:p.Asn262Lys
  • NP_001341620.1:p.Asn181Lys
  • NP_001341621.1:p.Asn181Lys
  • NP_001341622.1:p.Asn229Lys
  • NP_001341623.1:p.Asn181Lys
  • NP_001341624.1:p.Asn148Lys
  • NP_002871.1:p.Asn262Lys
  • NP_002871.1:p.Asn262Lys
  • LRG_413t1:c.786T>A
  • LRG_413t2:c.786T>A
  • LRG_413:g.64996T>A
  • LRG_413p1:p.Asn262Lys
  • LRG_413p2:p.Asn262Lys
  • NC_000003.11:g.12645683A>T
  • NM_002880.3:c.786T>A
  • NR_148940.3:n.1117T>A
  • NR_148941.3:n.1117T>A
  • NR_148942.3:n.1117T>A
  • c.786T>A
Protein change:
dbSNP: rs397516829
NCBI 1000 Genomes Browser:
Molecular consequence:
  • NM_001354689.3:c.786T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354690.3:c.786T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354691.3:c.543T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354692.3:c.543T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354693.3:c.687T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354694.3:c.543T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354695.3:c.444T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_002880.4:c.786T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NR_148940.3:n.1117T>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_148941.3:n.1117T>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_148942.3:n.1117T>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]


Noonan syndrome (NS)
Noonan's syndrome; Pseudo-Turner syndrome
MONDO: MONDO:0018997; MeSH: D009634; MedGen: C0028326; OMIM: PS163950

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV000061369Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
criteria provided, single submitter

(LMM Criteria)
(Sep 24, 2014)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenot provided11not providednot providednot providedclinical testing



Mutations in conserved regions 1, 2, and 3 of Raf-1 that activate transforming activity.

Chan EY, Stang SL, Bottorff DA, Stone JC.

Mol Carcinog. 2002 Apr;33(4):189-97.

PubMed [citation]

Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.

Kobayashi T, Aoki Y, Niihori T, Cavé H, Verloes A, Okamoto N, Kawame H, Fujiwara I, Takada F, Ohata T, Sakazume S, Ando T, Nakagawa N, Lapunzina P, Meneses AG, Gillessen-Kaesbach G, Wieczorek D, Kurosawa K, Mizuno S, Ohashi H, David A, Philip N, et al.

Hum Mutat. 2010 Mar;31(3):284-94. doi: 10.1002/humu.21187.

PubMed [citation]
See all PubMed Citations (3)

Details of each submission

From Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine, SCV000061369.6

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testing PubMed (3)


The Asn262Lys variant has been reported in two individuals with clinical feature s of a RASopathy and was identified to occur de novo in both individuals (Kobaya shi 2010, LMM unpublished). It was absent from large population studies. Computa tional prediction tools and conservation analysis suggest that this variant may impact the protein, though this information is not predictive enough to determin e pathogenicity. In vitro functional studies provide some evidence that the Asn2 62Lys variant may impact protein function (Chan 2002, Kobayashi 2010). However, these types of assays may not accurately represent biological function. Individu als with pathogenic variants in exon 7 or 17 in RAF1 have a high incidence of hy pertrophic cardiomyopathy (80-95%, Chan 2002). In summary, this variant meets ou r criteria to be classified as pathogenic (http://pcpgmwww.partners.org/personal izedmedicince/LMM).

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot providednot providednot providednot provided1not provided1not provided

Last Updated: Jun 10, 2023